The trial is designed to evaluate the safety and efficacy of ADXS-PSA as a monotherapy and in combination with Merck’s Keytruda, the first anti-PD-1 (programmed death receptor-1) therapy
The trial is designed to evaluate the safety of talimogene laherparepvec in combination with Merck’s FDA approved, anti-PD-1 therapy Keytruda, as well as the efficacy of this combination
As part of the deal, Merck will pay about $102 per share in cash, which represents a 35% premium to Cubist’s average stock price for the most recent
VAX2012Q incorporates a bacterial flagellin protein designed to improve the adaptive immune response to the vaccine. The trial is designed to evaluate the vaccine’s safety and immunogenicity in
The sNDA for a monotherapy indication is based on data from two double-blind, historical-controlled, multicenter randomized, Phase III trials (093-046 and 093-045) with identical study designs. The trials
The company said that Vimizim was reviewed under the Orphan Drug program and it is the first treatment approved in Australia for Morquio A syndrome, an ultra-rare, severely
During the trial, 30 patients with stage III-IV melanoma received about four cycles of pIL-12 EP into superficial cutaneous, subcutaneous and nodal lesions on days one, five and
The trial is designed to evaluate CPI-613, in combination with bendamustine and rituximab, in these NHL patients. CPI-613 is a first-in-class anticancer compound designed to disrupt the altered
Sources close to the matter have been cited by The Wall Street Journal as saying that the deal could be announced as early as this week. The acquisition
The application covers composition of matter for KP415, the company’s NME prodrug of methylphenidate. KP415 is designed to be a controlled release (CR), abuse-deterrent methylphenidate product and is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.